异quercitrin 通过抑制 PTP1B 调节的 IRS/PI3K/AKT 信号通路来改善胰岛素抵抗
Si-Yu Liu1,2,3, Lu-Jing Yu1,2, Sheng-Nan Zhang1
1Department of Pharmacy, the Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region, 541199, China.
Chinese journal of integrative medicine
|November 6, 2025
概括
异quercitrin (IS) 通过调节蛋白质氨酸酸酶1B (PTP1B) 和胰岛素受体基质/氨酸-3-酶/蛋白酶B信号通路,有效改善胰岛素抵抗 (IR). 这项研究阐明了IS背后的分子机制.
科学领域:
- 分子生物学分子生物学
- 生物化学 生物化学
- 内分泌学 在内分泌学.
背景情况:
- 胰岛素抵抗 (IR) 是糖尿病的一个标志,其特点是胰岛素信号受损.
- 蛋白氨酸酸酶1B (PTP1B) 是胰岛素信号的关键负调节剂,也是IR的治疗点.
- 异基 (IS) 是一种黄类化合物,在代谢性疾病管理中表现出潜力.
研究的目的:
- 研究PTP1B在调节IR中的分子机制.
- 为了确定异quercitrin (IS) 对PTP1B活性和胰岛素信号的 in vitro 和 in vivo 的影响.
主要方法:
- 在体外:在HepG2细胞中过度表达PTP1B,诱导IR模型,并使用IS治疗后使用qRT-PCR和西斑进行葡萄糖吸收和信号通路组件 (IRS/PI3K/AKT) 的评估.
- 在体内:在小鼠的尾部静脉注射Aav-PTP1B,其次是IS注射. 分析了代谢指标,胰腺形态和肝脏信号通路表达.
- 使用定量实时聚合酶连锁反应 (qRT-PCR) 和西班牙涂抹来评估基因和蛋白质表达水平.
主要成果:
- 在体外和体外模型中,IS显著改善了IR,降低了血糖,胆固醇和甘油三水平,控制了体重,并恢复了胰腺形态.
- IS 调节了 PTP1B 的表达,从而调节了 IRS/PI3K/AKT 信号通路.
- 治疗IS导致代谢指标和途径恒常性显著改善 (P<0.05或P<0.01).
结论:
- 异quercitrin (IS) 在改善胰岛素抵抗 (IR) 方面显示出显著的潜力.
- 通过PTP1B干预,IS通过抑制IRS/PI3K/AKT信号通路而起作用.
- 这些发现支持IS作为治疗糖尿病和相关代谢功能障碍的治疗剂.
相关概念视频
Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K
Dipeptidyl Peptidase 4 Inhibitors
570
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
570
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
Oral Hypoglycemic Agents: Biguanides and Glitazones
568
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
568
Regulation of the Unfolded Protein Response
2.9K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
2.9K


